IN8bio, Inc. (INAB) is a Biotechnology company in the Healthcare sector, currently trading at $1.38. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Analyst consensus target is INAB = $4 (+189.9% upside).
Valuation: INAB trades at a trailing Price-to-Earnings (P/E) of -0.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.
Net income is $19M (loss), growing at +8.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $3M against $28M equity (Debt-to-Equity (D/E) ratio 0.1, conservative). Current ratio is 8.82 (strong liquidity). Debt-to-assets is 8.6%. Total assets: $32M.
Analyst outlook: 3 / 4 analysts rate INAB as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 65/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 85/100 (Pass), Income ?/100 (Fail).
